Nuvectis Pharma (NVCT) Return on Assets (2022 - 2026)

Nuvectis Pharma has disclosed Return on Assets across 5 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Assets for Q1 2026 came in at 0.01%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY), and the FY2025 annual result was 0.01%, changed 0.0% from the prior year.
• Return on Assets came in at 0.01% for Q1 2026 at Nuvectis Pharma, down from 0.01% in the prior quarter.
• In the past five years, Return on Assets ranged from a high of 0.01% in Q3 2022 to a low of 0.01% in Q1 2022.
• The 5-year median for Return on Assets is 0.01% (2026), against an average of 0.01%.
• Peak annual rise in Return on Assets reached 0 bps in 2023, while the deepest fall reached 0 bps in 2023.
• Nuvectis Pharma's Return on Assets stood at 0.01% in 2022, then dropped by 27 bps to 0.01% in 2023, then advanced by 1 bps to 0.01% in 2024, then increased by 26 bps to 0.01% in 2025, then fell by 21 bps to 0.01% in 2026.
• The last three Return on Assets figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.